Sonoma Pharmaceuticals, Inc. announced on April 22, 2025, the registration of its hypochlorous acid-based acne products with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom. This regulatory approval paves the way for commercialization.
The company also announced the launch of these products through a prominent U.K. health and beauty retailer and pharmacy chain, which operates across more than 1,200 stores throughout the United Kingdom. This provides significant market access.
The innovative product line, including an acne toner and a balancing serum, will be sold under the retailer's own brand name. This strategic partnership and launch represent a major expansion into the U.K. retail dermatology market for Sonoma.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.